148 related articles for article (PubMed ID: 27651323)
1. Erdosteine reduces the exercise-induced oxidative stress in patients with severe COPD: Results of a placebo-controlled trial.
Dal Negro RW; Visconti M
Pulm Pharmacol Ther; 2016 Dec; 41():48-51. PubMed ID: 27651323
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of erdosteine 900 versus 600 mg/day in reducing oxidative stress in patients with COPD exacerbations: Results of a double blind, placebo-controlled trial.
Dal Negro RW; Visconti M; Turco P
Pulm Pharmacol Ther; 2015 Aug; 33():47-51. PubMed ID: 26116425
[TBL] [Abstract][Full Text] [Related]
3. Changes in blood ROS, e-NO, and some pro-inflammatory mediators in bronchial secretions following erdosteine or placebo: a controlled study in current smokers with mild COPD.
Dal Negro RW; Visconti M; Micheletto C; Tognella S
Pulm Pharmacol Ther; 2008; 21(2):304-8. PubMed ID: 17889580
[TBL] [Abstract][Full Text] [Related]
4. Erdosteine enhances airway response to salbutamol in patients with mild-to-moderate COPD.
Dal Negro R; Visconti M; Trevisan F; Bertacco S; Micheletto C; Tognella S
Ther Adv Respir Dis; 2008 Oct; 2(5):271-7. PubMed ID: 19124377
[TBL] [Abstract][Full Text] [Related]
5. Erdosteine reduces inflammation and time to first exacerbation postdischarge in hospitalized patients with AECOPD.
Moretti M; Fagnani S
Int J Chron Obstruct Pulmon Dis; 2015; 10():2319-25. PubMed ID: 26604731
[TBL] [Abstract][Full Text] [Related]
6. Erdosteine affects eicosanoid production in COPD.
Dal Negro RW; Visconti M; Tognella S; Micheletto C
Int J Clin Pharmacol Ther; 2011 Jan; 49(1):41-5. PubMed ID: 21176724
[TBL] [Abstract][Full Text] [Related]
7. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study.
Dal Negro RW; Wedzicha JA; Iversen M; Fontana G; Page C; Cicero AF; Pozzi E; Calverley PMA; ;
Eur Respir J; 2017 Oct; 50(4):. PubMed ID: 29025888
[TBL] [Abstract][Full Text] [Related]
8. Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation.
Calverley PM; Page C; Dal Negro RW; Fontana G; Cazzola M; Cicero AF; Pozzi E; Wedzicha JA
Int J Chron Obstruct Pulmon Dis; 2019; 14():2733-2744. PubMed ID: 31819405
[TBL] [Abstract][Full Text] [Related]
9. Erdosteine: its relevance in COPD treatment.
Moretti M
Expert Opin Drug Metab Toxicol; 2009 Mar; 5(3):333-43. PubMed ID: 19331595
[TBL] [Abstract][Full Text] [Related]
10. Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent.
Cazzola M; Page C; Rogliani P; Calzetta L; Matera MG
Drugs; 2020 Nov; 80(17):1799-1809. PubMed ID: 33025535
[TBL] [Abstract][Full Text] [Related]
11. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study.
Moretti M; Bottrighi P; Dallari R; Da Porto R; Dolcetti A; Grandi P; Garuti G; Guffanti E; Roversi P; De Gugliemo M; Potena A;
Drugs Exp Clin Res; 2004; 30(4):143-52. PubMed ID: 15553660
[TBL] [Abstract][Full Text] [Related]
12. Erdosteine: antitussive and anti-inflammatory effects.
Dal Negro RW
Lung; 2008; 186 Suppl 1():S70-3. PubMed ID: 18185958
[TBL] [Abstract][Full Text] [Related]
13. Melatonin reduces lung oxidative stress in patients with chronic obstructive pulmonary disease: a randomized, double-blind, placebo-controlled study.
de Matos Cavalcante AG; de Bruin PF; de Bruin VM; Nunes DM; Pereira ED; Cavalcante MM; Andrade GM
J Pineal Res; 2012 Oct; 53(3):238-44. PubMed ID: 22507631
[TBL] [Abstract][Full Text] [Related]
14. A controlled multicenter pediatric study in the treatment of acute respiratory tract diseases with the aid of a new specific compound, erdosteine (IPSE, Italian Pediatric Study Erdosteine).
Titti G; Lizzio A; Termini C; Negri P; Fazzio S; Mancini C
Int J Clin Pharmacol Ther; 2000 Aug; 38(8):402-7. PubMed ID: 10984014
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data.
Cazzola M; Floriani I; Page CP
Pulm Pharmacol Ther; 2010 Apr; 23(2):135-44. PubMed ID: 19854285
[TBL] [Abstract][Full Text] [Related]
16. Erdosteine protects HEI-OC1 auditory cells from cisplatin toxicity through suppression of inflammatory cytokines and induction of Nrf2 target proteins.
Kim SJ; Park C; Lee JN; Lim H; Hong GY; Moon SK; Lim DJ; Choe SK; Park R
Toxicol Appl Pharmacol; 2015 Oct; 288(2):192-202. PubMed ID: 26193055
[TBL] [Abstract][Full Text] [Related]
17. Use of thiols and implications for the use of inhaled corticosteroids in the presence of oxidative stress in COPD.
Cazzola M; Page CP; Wedzicha JA; Celli BR; Anzueto A; Matera MG
Respir Res; 2023 Jul; 24(1):194. PubMed ID: 37517999
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.
Rogliani P; Matera MG; Page C; Puxeddu E; Cazzola M; Calzetta L
Respir Res; 2019 May; 20(1):104. PubMed ID: 31133026
[TBL] [Abstract][Full Text] [Related]
19. Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis.
Cazzola M; Calzetta L; Page C; Rogliani P; Matera MG
Pulm Pharmacol Ther; 2018 Feb; 48():185-194. PubMed ID: 29233650
[TBL] [Abstract][Full Text] [Related]
20. New developments in the treatment of COPD: comparing the effects of inhaled corticosteroids and N-acetylcysteine.
van Overveld FJ; Demkow U; Górecka D; de Backer WA; Zielinski J
J Physiol Pharmacol; 2005 Sep; 56 Suppl 4():135-42. PubMed ID: 16204787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
